{
    "nct_id": "NCT06181266",
    "official_title": "A Phase 1/1b Study Evaluating the Safety, Pharmacology, and Clinical Effect of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer",
    "inclusion_criteria": "* Age ≥ 18 years\n* Histologically documented recurrence of NMIBC\n* BCG unresponsive (BCG naïve patients may be enrolled if they have received at least 1 line of adequate intravesical standard of care (SOC) treatment and are either not candidates for BCG or do not have access to BCG (e.g., BCG shortage))\n* Eastern Cooperative Oncology Group Performance Status 0-1\n* Adequate organ and marrow function\n* Highly effective contraception if risk of conception exists.\n* A female participant is eligible if not pregnant, not breastfeeding, not a woman of childbearing potential (WOCBP) or is a WOCBP that uses highly effective contraception.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 99 Years",
    "exclusion_criteria": "* Received treatment with any local or systemic antineoplastic therapy within 3 weeks or 5× the plasma half-life prior to first dose of ZH9\n* Major surgery or radiation within the 3 weeks prior to Screening (TURBT is not considered major surgery)\n* Concurrent urinary tract infection or history of clinically significant polyuria\n* Symptoms consistent with typhoid\n* Evidence of infection within 2 weeks of the first dose of ZH9\n* Significant 12-lead electrocardiogram abnormalities\n* History of malignancy within the previous 12 months\n* History of allogeneic tissue/solid organ transplant",
    "miscellaneous_criteria": ""
}